CLINICAL TRIALS PROFILE FOR TENAPANOR HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for TENAPANOR HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01764854 ↗ | Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis | Completed | AstraZeneca | Phase 2 | 2013-01-01 | The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing fluid overload/weight gain between dialysis sessions for patients with End Stage Renal Disease on Hemodialysis. |
| NCT01764854 ↗ | Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis | Completed | Ardelyx | Phase 2 | 2013-01-01 | The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing fluid overload/weight gain between dialysis sessions for patients with End Stage Renal Disease on Hemodialysis. |
| NCT02176252 ↗ | Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects | Completed | AstraZeneca | Phase 1 | 2013-07-01 | The study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy Japanese subjects at increasing doses given for 7 days in order to allow for including Japanese subjects in future global studies. A cohort of Caucasian subjects will be included in the study to evaluate cardiac effects, assessed by digital ECGs (dECG) recordings, also in Caucasian subjects. |
| NCT02176252 ↗ | Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects | Completed | Ardelyx | Phase 1 | 2013-07-01 | The study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy Japanese subjects at increasing doses given for 7 days in order to allow for including Japanese subjects in future global studies. A cohort of Caucasian subjects will be included in the study to evaluate cardiac effects, assessed by digital ECGs (dECG) recordings, also in Caucasian subjects. |
| NCT02249936 ↗ | A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations | Completed | AstraZeneca | Phase 1 | 2013-02-01 | The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of different formulations of AZD1722 in healthy male and female subjects taking Omeprazole. |
| NCT02249936 ↗ | A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations | Completed | Ardelyx | Phase 1 | 2013-02-01 | The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of different formulations of AZD1722 in healthy male and female subjects taking Omeprazole. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TENAPANOR HYDROCHLORIDE
Condition Name
| Condition Name for TENAPANOR HYDROCHLORIDE | |
| Intervention | Trials |
| Hyperphosphatemia | 6 |
| Healthy | 4 |
| Constipation Predominant Irritable Bowel Syndrome | 3 |
| Irritable Bowel Syndrome With Constipation (IBS-C) | 2 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for TENAPANOR HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for TENAPANOR HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for TENAPANOR HYDROCHLORIDE
Sponsor Name
